Analysts tracking EW project a potential 6–8% gain over the next 60 days, given improving margins and robust cash flow. The stock has maintained low beta volatility, which appeals to investors seeking stability during market pullbacks. Diving deeper into the forecasts for Edwards Lifesciences mentioned earlier will help you understand how analysts view the stock going forward. So feel free to check out our free graph representing analyst forecasts . We have seen 483 institutional investors add shares of $EW stock to their portfolio, and 623 decrease their positions in their most recent quarter. EW’s fundamental outlook remains solid with operating margin guidance raised to 26%. This underpins analyst forecasts pegging short-term price movement between $94 and $98.
